Darolutamide, hormone therapy and low-dose docetaxel for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs (darolutamide plus hormone therapy) along with a low dose of chemotherapy (docetaxel) for men whose prostate cancer has spread to other parts of the body. It aims to see if this combined approach is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult male at least 18 years old.
- You must have prostate cancer that has spread to bones or other organs (confirmed by scans).
- You must be a candidate for both hormone therapy (ADT) and chemotherapy (docetaxel).
- If you already started hormone therapy, it must have been within the last 12 weeks.
- You must be in good enough health to be up and about most of the day (ECOG score 0 or 1).
- You cannot have had certain other prostate cancer treatments like abiraterone, enzalutamide, or prior chemotherapy for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
This trial tests a new way of using darolutamide (a hormone therapy) together with standard chemotherapy (docetaxel) and hormone therapy (ADT) for men with prostate cancer that has spread. The goal is to see if taking darolutamide on an intermittent schedule works as well as continuous treatment.
This study tests combining targeted radiation therapy (guided by special imaging) with a hormone-blocking medication called darolutamide in men with prostate cancer that has spread to other parts of the body. The goal is to see if this combination works better than standard treatment alone.
This trial tests a combination of darolutamide (a pill that blocks male hormones) and standard hormone therapy (ADT) for men with high-risk prostate cancer that has not spread beyond the pelvis, after their prostate has been removed. The goal is to see if this treatment can help prevent the cancer from coming back.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This study watches how well a drug called darolutamide works when combined with hormone therapy for men with prostate cancer that has returned after previous treatment. The goal is to understand if this combination helps prevent cancer spread and is safe to use.
Hear when a new mHSPC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.